6533b820fe1ef96bd1279b9c
RESEARCH PRODUCT
Should organs from hepatitis C-positive donors be used in hepatitis C-negative recipients for liver transplantation?
Nazia SelznerMarina Berenguersubject
Liver surgerymedicine.medical_specialtySustained Virologic ResponseWaiting ListsHepatitis C virusmedicine.medical_treatmentMEDLINEHepacivirus030230 surgeryLiver transplantationmedicine.disease_causeAntiviral AgentsDonor SelectionEnd Stage Liver Disease03 medical and health sciences0302 clinical medicinemedicineHumansIntensive care medicineTransplantationHepatologybusiness.industryTransmission (medicine)Treatment optionsHepatitis Cmedicine.diseaseAllograftsHepatitis CTissue DonorsTransplant RecipientsLiver TransplantationLiverWaiting list030211 gastroenterology & hepatologySurgerybusinessdescription
Given the scarcity of donated organs and the frequency of death on the waiting list, strategies that could improve the available supply of high-quality liver grafts are much needed. Direct-acting antiviral agent (DAA) regimens have proved to be highly effective to treat hepatitis C virus (HCV), even in the setting of posttransplantation. The question arises as to whether transplant communities should consider the utilization of HCV-positive donors into HCV-negative recipients. This review summarizes risk of transmission, treatment options with success rate, and ethical considerations for usage of HCV-positive donors. Liver Transplantation 24 831-840 2018 AASLD.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2018-06-01 | Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society |